F. Hoffmann-La Roche AG

Address
Grenzacherstrasse 124

Sponsor Overview

assignment
222
sponsored trials
science
150
molecules
location_city
1308
research centres
public
27
countries
person_search
3321
investigators

Specializations

Oncology

F. Hoffmann-La Roche AG funds a broad oncology portfolio spanning breast cancer, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, colorectal cancer, and urothelial carcinoma, with additional activity in lymphoma, multiple myeloma, and other solid tumours.

  • Breast cancer
  • Non-small cell lung cancer
  • Lymphoma
  • Hepatocellular carcinoma
  • Urothelial carcinoma

Its oncology research also includes biomarker-defined disease groups such as HER2-positive, hormone receptor-positive, PIK3CA-mutated, KRAS G12C-mutated, and ALK-rearranged cancers.

Neurology

The sponsor maintains strong interest in neurological disease, particularly multiple sclerosis across relapsing, progressive, and primary progressive forms, as well as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Angelman syndrome, and spinal muscular atrophy.

  • Multiple sclerosis
  • Alzheimer’s disease
  • Parkinson’s disease
  • Huntington’s disease
  • Spinal muscular atrophy

Research also extends to neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and autoimmune encephalitis.

Immunology and Inflammatory Disease

Roche supports studies in rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, Crohn’s disease, ulcerative colitis, atopic dermatitis, asthma, and chronic obstructive pulmonary disease.

  • Rheumatoid arthritis
  • Systemic lupus erythematosus
  • Crohn’s disease
  • Ulcerative colitis
  • Atopic dermatitis

Additional work covers thyroid eye disease, IgA nephropathy, primary membranous nephropathy, and paroxysmal nocturnal hemoglobinuria.

Ophthalmology and Vision Disorders

The sponsor is active in ophthalmology, with trials in neovascular age-related macular degeneration, choroidal neovascularization secondary to pathologic myopia, uveitic macular edema, and thyroid eye disease.

  • Neovascular age-related macular degeneration
  • Uveitic macular edema
  • Choroidal neovascularization
  • Thyroid eye disease
  • Visual function

These studies include conditions affecting retinal and orbital inflammation, with attention to preserving visual acuity and related ocular outcomes.

Hematology, Metabolic, and Rare Diseases

Roche also funds research in hemophilia A, sickle cell disease, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and selected kidney diseases such as primary IgA nephropathy and lupus nephritis.

  • Hemophilia A
  • Sickle cell disease
  • Paroxysmal nocturnal hemoglobinuria
  • Atypical hemolytic uremic syndrome
  • Primary IgA nephropathy

Its broader programme includes obesity, type 2 diabetes mellitus, hepatic impairment, and studies in healthy volunteers to support development across therapeutic areas.

Sponsored Trials

Trial Name Country Status
A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple SclerosisFrance FranceGermany GermanyHungary HungaryItaly ItalyPoland PolandPortugal PortugalSpain SpainRecruiting
A Phase 1 Study of Afimkibart Effects on Cytochrome P450-Mediated Drug Metabolism in Patients With Active Ulcerative ColitisBelgium BelgiumGermany GermanyPoland PolandRecruiting
A Phase 1, First-in-Human Study to Evaluate the Safety and Pharmacokinetics of RO7812653 in Patients with Early Symptomatic Alzheimer’s DiseasePoland PolandSpain SpainSweden SwedenThe Netherlands The NetherlandsRecruiting
A Phase I Study to Evaluate the Safety and Pharmacokinetics of RO7763505 in Healthy Volunteers and Patients with Stable Coronary Artery DiseaseThe Netherlands The NetherlandsRecruiting
A Phase I Study to Evaluate the Safety, Absorption, and Elimination of RO7795081 in Subjects with Type 2 Diabetes and OverweightThe Netherlands The NetherlandsNot Recruiting
A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Absorption of RO7795068 in Subjects with ObesityThe Netherlands The NetherlandsNot Recruiting
A Phase IB, Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso‑Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)France FranceItaly ItalySpain SpainThe Netherlands The NetherlandsNot Recruiting
A PHASE IB/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCEULLULAR CARCINOMA (MORPHEUS-NEO HCC)Austria AustriaFrance FranceGermany GermanySpain SpainNot Recruiting
A Phase IB/IIA, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 following Intravenous Infusion in Patients with Prodromal or Mild To Moderate Alzheimer’s DiseasePoland PolandSpain SpainNot Recruiting
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerCzechia CzechiaDenmark DenmarkGermany GermanyHungary HungaryItaly ItalyPoland PolandSpain SpainThe Netherlands The NetherlandsNot Recruiting
1–10 of 222
1 / 23

Data & Insights

science
Molecule Portfolio
Compounds under investigation
28
Exclusive Molecules
out of 150 total (19% not shared with other sponsors)

This sponsor works with 150 molecules, of which 28 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
59%
Return partnership rate
774 of 1308 sites collaborated multiple times

This sponsor has worked with 1308 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Neoplasms103 trials
    853 other sponsors
  • 2.
    Nervous System Diseases46 trials
    449 other sponsors
  • 3.
    Immune System Diseases18 trials
    322 other sponsors
  • 4.
    Hemic and Lymphatic Diseases16 trials
    249 other sponsors
  • 5.
    Not possible to specify10 trials
    220 other sponsors
  • 6.
    Eye Diseases9 trials
    138 other sponsors
  • 7.
    Nutritional and Metabolic Diseases9 trials
    211 other sponsors
  • 8.
    Immune System Phenomena8 trials
    15 other sponsors
  • 9.
    Digestive System Diseases6 trials
    280 other sponsors
  • 10.
    Environment and Public Health6 trials
    7 other sponsors
  • 11.
    Musculoskeletal Diseases6 trials
    238 other sponsors
  • 12.
    Population Characteristics5 trials
    3 other sponsors
  • 13.
    Congenital, Hereditary, and Neonatal Diseases and Abnormalities4 trials
    165 other sponsors
  • 14.
    Behavioral Disciplines and Activities3 trials
    20 other sponsors
  • 15.
    Respiratory Tract Diseases2 trials
    277 other sponsors
  • 16.
    Cardiovascular Diseases1 trial
    359 other sponsors
  • 17.
    Chemical Phenomena1 trial
    2 other sponsors
  • 18.
    Female Urogenital Diseases and Pregnancy Complications1 trial
    142 other sponsors
  • 19.
    Immune system processes1 trial
    65 other sponsors
  • 20.
    Male Urogenital Diseases1 trial
    111 other sponsors
  • 21.
    Metabolism1 trial
    38 other sponsors
  • 22.
    Skin and Connective Tissue Diseases1 trial
    247 other sponsors

Partnered Research Centres

1308 centres
location_city
assignment1
"MEDICAL CENTER - BILEVA" LTD
Address
Blagoevgrad Region, Blagoevgrad Municipality,, City of Blagoevgrad, 17 Aleko Konstantinov St, 2700 Blagoevgrad
Learn morearrow_forward
location_city
assignment2
"Santa Maria della Speranza" Hospital
Address
Via Fiorignano 1, 84091 Battipaglia
Learn morearrow_forward
location_city
assignment60
4 Wojskowy SzpitaKliniczny Z Polikliniką Samodzielny Publiczny ZakładOpieki ZdrowotneWe Wrocławiu
Address
Ul. Rudolfa Weigla 5, 53-114 Wroclaw
Learn morearrow_forward
location_city
assignment23
401 General Military Hospital Of Athens
Address
Panagioti Kanellopoulou Av 1, 115 25 Athens
Learn morearrow_forward
location_city
assignment103
A.O.U. Policlinico G. Martino Di Messina
Address
Via Consolare Valeria N 1, 98124 Messina
Learn morearrow_forward
location_city
assignment335
Aalborg University Hospital
Address
Moelleparkvej 4, 9000 Aalborg
Learn morearrow_forward
Page 1 of 218

Want to get in touch with this sponsor?

Send a question and we'll pass it on to F. Hoffmann-La Roche AG.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.